Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

Inhibiting HIF2A for idiopathic pulmonary fibrosis

April 1, 2025 3:44 AM UTC

Inhibiting the transcription factor HIF2A could help treat idiopathic pulmonary fibrosis by preventing the proliferation of pro-fibrotic epithelial cell populations in the lung, while promoting alveolar epithelial cell repair.

Bioinformatic analysis of public data sets identified higher HIF1A and HIF2A signaling in pro-fibrotic lung epithelial cells from pulmonary fibrosis patients than in those from individuals without pulmonary fibrosis. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article